Ona Therapeutics develops antibody-drug conjugates and therapies for the treatment of advanced and treatment-resistant cancers.
Ona Therapeutics has raised $86.6M in total funding. The most recent round was Series B. The last funding was announced in June 2026.
Ona Therapeutics's investors include Bpifrance, Cofides, Columbus Venture Partners, Ysios Capital, Asabys Partners.
Ona Therapeutics is headquartered in Barcelona, Spain.
Ona Therapeutics develops antibody-drug conjugates and therapies for the treatment of advanced and treatment-resistant cancers.
Ona Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ona Therapeutics — Funding & Investors." VCBacked, June 4, 2026, https://www.vcbacked.co/company/ona-therapeutics. Accessed July 19, 2026.
VCBacked. (2026). Ona Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/ona-therapeutics
{{cite web |title=Ona Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/ona-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated